GPR55 and Cognitive impairment: For example, O-1602, a synthetic GPR55 agonist reversed β amyloid-induced cognitive impairment and release of pro-inflammatory cytokines as well as the production of reactive oxygen species and cell death in mice, suggesting GPR55 as a promising target to treat AD [10].